ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
Filing Information
| Accession Number | 0001735276-26-000015 |
|---|---|
| Form Type | 4 |
| Filing Date | Jan 14, 2026 |
| Document Date | Jan 11, 2026 |
| Document | View SEC Filing |
Transactions
22
Total Shares
5,310
Total Value
$547,928.97
P&L
+inf% (+$1,186,246.00)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP Chief R&D | Common Stock | โ | Jan 11, 2026 | Grant/Award | 3,800 | $0.00 | $0.00 | 24,021 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 39 | $353.95 | $13,804.05 | 23,982 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 42 | $355.16 | $14,916.72 | 23,940 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 41 | $356.09 | $14,599.69 | 23,899 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 96 | $357.17 | $34,288.32 | 23,803 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 123 | $358.18 | $44,056.14 | 23,680 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 85 | $359.14 | $30,526.90 | 23,595 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 155 | $360.22 | $55,834.10 | 23,440 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 98 | $361.45 | $35,422.10 | 23,342 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 73 | $362.38 | $26,453.74 | 23,269 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 47 | $363.55 | $17,086.85 | 23,222 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 199 | $364.83 | $72,601.17 | 23,023 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 220 | $365.56 | $80,423.20 | 22,803 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 50 | $366.41 | $18,320.50 | 22,753 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 41 | $367.40 | $15,063.40 | 22,712 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 92 | $368.62 | $33,913.04 | 22,620 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 40 | $369.48 | $14,779.20 | 22,580 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 18 | $370.87 | $6,675.66 | 22,562 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 3 | $372.46 | $1,117.38 | 22,559 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 14 | $374.44 | $5,242.16 | 22,545 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 19 | $375.65 | $7,137.35 | 22,526 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Jan 12, 2026 | Sale | 15 | $377.82 | $5,667.30 | 22,511 | Direct | โ | View Details |